(SNN) Smith & Nephew SNATS - Ratings and Ratios
Knee Implants, Hip Implants, Wound Care, Sports Medicine, Orthopaedic Devices
SNN EPS (Earnings per Share)
SNN Revenue
Description: SNN Smith & Nephew SNATS
Smith & Nephew plc (NYSE:SNN) is a leading global medical technology company that develops, manufactures, and markets a diverse range of medical devices and services across three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The companys product portfolio includes knee and hip implants, trauma and extremities products, sports medicine joint repair products, arthroscopic enabling technologies, and advanced wound care products.
From a business perspective, SNNs revenue streams are diversified across various geographies and product categories, with a significant presence in the United Kingdom, the United States, and internationally. The companys customer base comprises healthcare providers, and its products are used in a range of medical procedures, including knee and hip replacements, sports medicine surgeries, and wound care treatments. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and operating margin improvement, which are critical in assessing the companys ability to drive profitability and cash flow generation.
In terms of key metrics, SNNs market capitalization stands at approximately $13.7 billion, with a forward price-to-earnings (P/E) ratio of 14.03, indicating a relatively attractive valuation compared to its historical averages. The companys return on equity (ROE) is around 11.68%, suggesting a decent return on shareholders capital. To further evaluate SNNs performance, investors may also want to monitor metrics such as research and development (R&D) expenditure as a percentage of revenue, sales and marketing expenses as a percentage of revenue, and the companys cash conversion cycle.
To gain a deeper understanding of SNNs prospects, its essential to analyze the companys competitive positioning within the medical technology industry, its product pipeline, and its ability to drive innovation through R&D investments. Additionally, investors should keep a close eye on industry trends, regulatory changes, and macroeconomic factors that may impact the demand for SNNs products and services. By examining these factors and KPIs, investors can make more informed decisions about SNNs potential for long-term growth and returns.
SNN Stock Overview
| Market Cap in USD | 16,302m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1999-11-16 |
SNN Stock Ratings
| Growth Rating | 49.1% |
| Fundamental | 71.8% |
| Dividend Rating | 41.8% |
| Return 12m vs S&P 500 | 4.06% |
| Analyst Rating | 3.75 of 5 |
SNN Dividends
| Dividend Yield 12m | 3.17% |
| Yield on Cost 5y | 2.96% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 95.3% |
| Payout Ratio | 113.6% |
SNN Growth Ratios
| Growth Correlation 3m | 94.9% |
| Growth Correlation 12m | 58.6% |
| Growth Correlation 5y | -49.4% |
| CAGR 5y | 19.41% |
| CAGR/Max DD 3y | 0.58 |
| CAGR/Mean DD 3y | 2.28 |
| Sharpe Ratio 12m | 1.15 |
| Alpha | 1.37 |
| Beta | 0.994 |
| Volatility | 23.64% |
| Current Volume | 1032.7k |
| Average Volume 20d | 603.9k |
| Stop Loss | 36.6 (-3.1%) |
| Signal | -1.56 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (814.6m TTM) > 0 and > 6% of Revenue (6% = 612.7m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 5.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.20% (prev 21.13%; Δ 9.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 1.51b > Net Income 814.6m (YES >=105%, WARN >=100%) |
| Net Debt (2.78b) to EBITDA (2.22b) ratio: 1.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (439.9m) change vs 12m ago -49.60% (target <= -2.0% for YES) |
| Gross Margin 69.95% (prev 70.14%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 98.80% (prev 83.34%; Δ 15.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.98 (EBITDA TTM 2.22b / Interest Expense TTM 254.8m) >= 6 (WARN >= 3) |
Altman Z'' 5.29
| (A) 0.29 = (Total Current Assets 4.62b - Total Current Liabilities 1.54b) / Total Assets 10.68b |
| (B) 0.48 = Retained Earnings (Balance) 5.12b / Total Assets 10.68b |
| (C) 0.12 = EBIT TTM 1.27b / Avg Total Assets 10.33b |
| (D) 0.96 = Book Value of Equity 4.96b / Total Liabilities 5.15b |
| Total Rating: 5.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.82
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 4.63% = 2.32 |
| 3. FCF Margin 8.80% = 2.20 |
| 4. Debt/Equity 0.68 = 2.27 |
| 5. Debt/Ebitda 1.70 = 0.59 |
| 6. ROIC - WACC 4.10% = 5.13 |
| 7. RoE 15.37% = 1.28 |
| 8. Rev. Trend 47.93% = 2.40 |
| 9. Rev. CAGR 35.34% = 2.50 |
| 10. EPS Trend 45.30% = 1.13 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of SNN shares?
Over the past week, the price has changed by -1.61%, over one month by +3.17%, over three months by +28.90% and over the past year by +23.06%.
Is Smith & Nephew SNATS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNN is around 36.54 USD . This means that SNN is currently overvalued and has a potential downside of -3.28%.
Is SNN a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.4 | -0.9% |
| Analysts Target Price | 37.4 | -0.9% |
| ValueRay Target Price | 40.6 | 7.5% |
Last update: 2025-09-03 04:47
SNN Fundamental Data Overview
CCE Cash And Equivalents = 675.4m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 33.4375
P/E Forward = 15.7978
P/S = 2.7427
P/B = 2.9448
P/EG = 1.0411
Beta = 0.618
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.61b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.77b USD (Calculated: Short Term 156.9m + Long Term 3.61b)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 19.40b USD (16.30b + Debt 3.77b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
FCF Yield = 4.63% (FCF TTM 898.3m / Enterprise Value 19.40b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Tobins Q-Ratio = 3.91 (Enterprise Value 19.40b / Book Value Of Equity 4.96b)
Interest Expense / Debt = 2.17% (Interest Expense 81.7m / Debt 3.77b)
Taxrate = 17.27% (86.0m / 498.0m)
NOPAT = 1.05b (EBIT 1.27b * (1 - 17.27%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.68 (Debt 3.77b / last Quarter total Stockholder Equity 5.53b)
Debt / EBITDA = 1.70 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 4.20 (Debt 3.77b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean)
RoA = 7.63% (Net Income 814.6m, Total Assets 10.68b )
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 14.24% (Ebit 1.27b / (Equity 5.30b + L.T.Debt 3.61b))
RoIC = 12.30% (NOPAT 1.05b / Invested Capital 8.53b)
WACC = 8.20% (E(16.30b)/V(20.07b) * Re(9.68%)) + (D(3.77b)/V(20.07b) * Rd(2.17%) * (1-Tc(0.17)))
Shares Correlation 3-Years: -35.67 | Cagr: -6.07%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 73.69% ; FCFE base≈658.4m ; Y1≈705.3m ; Y5≈858.7m
Fair Price DCF = 26.00 (DCF Value 11.32b / Shares Outstanding 435.3m; 5y FCF grow 7.97% → 3.0% )
Revenue Correlation: 47.93 | Revenue CAGR: 35.34%
Rev Growth-of-Growth: 15.44
EPS Correlation: 45.30 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -70.35
Additional Sources for SNN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle